OAFI FOUNDATION HOSTED THE LAUNCHING OF THE ORGANIZATION EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY On January 23rd and 24th, in Barcelona, the OAFI Foundation hosted the launching of the European Cooperation in Science and Technology, (COST), a funding organization for research and innovation networks at European...
OAFI Radio's programme "Fibromyalgia, chronic fatigue syndrome and adequate exercise" has been awarded first prize in the Grünenthal Foundation's Journalism Awards, dedicated to chronic pain, in the audiovisual media category. On 12 December, the OAFI Foundation won first prize in the 13th Grünenthal Foundation Journalism Awards...
- The scholarships will help 6 young athletes from our country to develop their sports career in an optimal and healthy way. - The award ceremony took place this Tuesday at Kern Pharma's headquarters in Terrassa (Barcelona). The Osteoarthritis Foundation International (OAFI), the pharmaceutical laboratory Kern Pharma...
The agreement, signed this Tuesday by Dr. Josep Vergés, Founder and President of OAFI, and Prof. F. Javier de la Mata, Vice-Rector for Research and Transfer of the University of Alcalá, will focus on pharmacological research into osteoarthritis and the locomotor system. The Osteoarthritis Foundation International...
AECOSAR participated this past Sunday, May 22, in the II Solidarity Race for Patients with Rheumatic Diseases, organized by the Society of Rheumatology of the Community of Madrid (SORCOM). They were also awarded for the support of the ARTRO 360 project, an initiative of OAFI...
In recent years, a number of health forums and online patient communities have emerged. Within these platforms, patients exchange information about their experiences with chronic illness. These communities provide a space where patients can discuss and share their experiences on issues of concern to them....
The Osteoarthritis Foundation International (OAFI), the Spanish Osteoporosis Association (AECOSAR) and the Banco Farmacéutico, together with the Observatorio de la Pobreza Farmacéutica, signed an agreement last January establishing a joint working framework to curb pharmaceutical poverty in patients with osteoarthritis and/or osteoporosis. OAFI is the world's...
The agreement, signed during the month of November, aims to further research into these bone diseases, adding the patient's perspective.The main objective of the collaboration, a pioneer in the sector, is to promote the prevention, treatment and improvement of the quality of life of patients,...
Dr. Vergés, CEO & Founder of OAFI, appeared last Tuesday 28th September before the Health and Consumer Commission of the Spanish Senate. Dr. Josep Vergés, on behalf of OAFI and AECOSAR, presented to the senators the work that these two associations carry out on a daily...
Diet is a key factor in the improvement of osteoarthritis, not only to achieve weight loss, but for the benefits it can have on our joint health. OAFI, always seeking to improve the quality of life and health of osteoarthritis patients, is committed to improving...